Triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer characterized by lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), has significantly poorer outcomes than non-TNBC subtypes due to the natural history of this life-threating disease and lack of endocrine and target therapies [1, 2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.